{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:14:56Z","timestamp":1793157296019,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neurol.2025.07.016","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:43:21Z","timestamp":1762962201000},"page":"881-892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The challenging concept of preclinical Alzheimer's disease"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2634-7198","authenticated-orcid":false,"given":"D.","family":"Wallon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-3608","authenticated-orcid":false,"given":"A.","family":"Garnier-Crussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2025.07.016_bib0395","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.07.016_bib0400","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13195-018-0459-7","article-title":"Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis","volume":"11","author":"Parnetti","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2025.07.016_bib0405","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1037\/0894-4105.8.3.374","article-title":"Preclinical cognitive markers of dementia of the Alzheimer type","volume":"8","author":"Bondi","year":"1994","journal-title":"Neuropsychology"},{"key":"10.1016\/j.neurol.2025.07.016_bib0410","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.07.016_bib0415","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/alz.12694","article-title":"Global estimates on the number of persons across the Alzheimer's disease continuum","volume":"19","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.07.016_bib0420","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","article-title":"Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease","volume":"14","author":"Brookmeyer","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.07.016_bib0425","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.07.016_bib0430","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.07.016_bib0435","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0440","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0445","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","article-title":"The probabilistic model of Alzheimer disease: the amyloid hypothesis revised","volume":"23","author":"Frisoni","year":"2022","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.neurol.2025.07.016_bib0450","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.07.016_bib0455","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer disease as a clinical-biological construct\u2014An International Working Group Recommendation","volume":"81","author":"Dubois","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0460","doi-asserted-by":"crossref","first-page":"e209753","DOI":"10.1212\/WNL.0000000000209753","article-title":"Influence of different diagnostic criteria on Alzheimer disease clinical research","volume":"103","author":"Bieger","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.07.016_bib0465","series-title":"Diagnosis of Alzheimer's disease: French recommendations from the Federation of Memory Centers","author":"Dumurgier","year":"2025"},{"key":"10.1016\/j.neurol.2025.07.016_bib0470","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00115-023-01492-6","article-title":"Die S3-Leitlinien Demenzen","volume":"94","author":"Jessen","year":"2023","journal-title":"Nervenarzt"},{"key":"10.1016\/j.neurol.2025.07.016_bib0475","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","article-title":"Neuropathology of older persons without cognitive impairment from two community-based studies","volume":"66","author":"Bennett","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.07.016_bib0480","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2025.07.016_bib0485","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0490","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2025.07.016_bib0495","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaneurol.2022.2379","article-title":"Association of elevated amyloid and tau Positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment","volume":"79","author":"Strikwerda-Brown","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0500","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.jalz.2007.11.017","article-title":"The pre\u2013mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease","volume":"4","author":"Reisberg","year":"2008","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.07.016_bib0505","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1212\/WNL.0000000000001712","article-title":"Subjective cognitive concerns, amyloid-\u03b2, and neurodegeneration in clinically normal elderly","volume":"85","author":"Amariglio","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.07.016_bib0510","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jalz.2015.12.013","article-title":"Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease","volume":"12","author":"Buckley","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.07.016_bib0515","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/alz.12512","article-title":"Characteristics of subjective cognitive decline associated with amyloid positivity","volume":"18","author":"Janssen","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.07.016_bib0520","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jalz.2012.08.004","article-title":"Cerebrospinal fluid A\u03b242 is the best predictor of clinical progression in patients with subjective complaints","volume":"9","author":"Van Harten","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.07.016_bib0525","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.neurobiolaging.2012.06.014","article-title":"Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals","volume":"34","author":"Sperling","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurol.2025.07.016_bib0530","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2025.07.016_bib0535","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1037\/neu0000867","article-title":"Cognitive intraindividual variability as a potential biomarker for early detection of cognitive and functional decline","volume":"37","author":"Scott","year":"2023","journal-title":"Neuropsychology"},{"key":"10.1016\/j.neurol.2025.07.016_bib0540","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41582-018-0031-x","article-title":"Spatial navigation deficits\u00a0\u2014\u00a0overlooked cognitive marker for preclinical Alzheimer disease?","volume":"14","author":"Coughlan","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0545","doi-asserted-by":"crossref","first-page":"e207978","DOI":"10.1212\/WNL.0000000000207978","article-title":"Cognitive and functional change over time in cognitively healthy individuals according to Alzheimer disease biomarker-defined subgroups","volume":"102","author":"Dubbelman","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.07.016_bib0550","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2025.07.016_bib0555","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","article-title":"Tangles and plaques in nondemented aging and preclinical Alzheimer's disease","volume":"45","author":"Price","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0560","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41582-022-00642-9","article-title":"Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes","volume":"18","author":"G\u00f3mez-Isla","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0565","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13195-019-0479-y","article-title":"Concepts for brain aging: resistance, resilience, reserve, and compensation","volume":"11","author":"Montine","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2025.07.016_bib0570","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(18)30371-5","article-title":"Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project","volume":"18","author":"Wallace","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0575","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.0000000000005303","article-title":"Resistance vs. resilience to Alzheimer disease: clarifying terminology for preclinical studies","volume":"90","author":"Arenaza-Urquijo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.07.016_bib0580","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/brain\/awv236","article-title":"The preclinical phase of the pathological process underlying sporadic Alzheimer's disease","volume":"138","author":"Braak","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2025.07.016_bib0585","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jalz.2016.11.005","article-title":"Synergistic interaction between amyloid and tau predicts the progression to dementia","volume":"13","author":"Pascoal","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.07.016_bib0590","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/brain\/awab099","article-title":"Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease","volume":"144","author":"Spina","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2025.07.016_bib0595","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","article-title":"Mixed brain pathologies account for most dementia cases in community-dwelling older persons","volume":"69","author":"Schneider","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.07.016_bib0600","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2025.07.016_bib0605","doi-asserted-by":"crossref","first-page":"e209866","DOI":"10.1212\/WNL.0000000000209866","article-title":"Lumipulse-measured cerebrospinal fluid biomarkers for the early detection of Alzheimer disease","volume":"103","author":"Safransky","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2025.07.016_bib0610","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0615","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJMoa2310168","article-title":"Biomarker changes during 20 years preceding Alzheimer's disease","volume":"390","author":"Jia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2025.07.016_bib0620","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","article-title":"Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs. tau positron emission tomography","volume":"80","author":"Therriault","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0625","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","article-title":"CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease","volume":"29","author":"Horie","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2025.07.016_bib0630","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jamaneurol.2014.2031","article-title":"Synergistic effect of \u03b2-amyloid and neurodegeneration on cognitive decline in clinically normal individuals","volume":"71","author":"Mormino","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0635","doi-asserted-by":"crossref","first-page":"e70076","DOI":"10.1111\/ene.70076","article-title":"Hippocampal subfield volume in relation to cerebrospinal fluid amyloid-\u00df in early Alzheimer's disease: diagnostic utility of 7T MRI","volume":"32","author":"Adeyemi","year":"2025","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0640","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer's disease: current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.neurol.2025.07.016_bib0645","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2025.07.016_bib0650","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs. other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2025.07.016_bib0655","doi-asserted-by":"crossref","first-page":"e14537","DOI":"10.1002\/alz.14537","article-title":"Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window","volume":"21","author":"Yakoub","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.07.016_bib0660","doi-asserted-by":"crossref","first-page":"103836","DOI":"10.1016\/j.ebiom.2022.103836","article-title":"Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease","volume":"76","author":"Ashton","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.neurol.2025.07.016_bib0665","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41582-024-01004-3","article-title":"Disentangling clinical and biological trajectories of neurodegenerative diseases","volume":"20","author":"Villain","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0670","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer's disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2025.07.016_bib0675","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/brain\/awad005","article-title":"Anti-amyloid antibody therapies in Alzheimer's disease","volume":"146","author":"Perneczky","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2025.07.016_bib0680","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2025.07.016_bib0685","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1474-4422(25)00024-9","article-title":"Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2\/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial","volume":"24","author":"Bateman","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0690","first-page":"150","volume":"4","author":"Tariot","year":"2018","journal-title":"Alzheimers Dement Transl Res Clin"},{"key":"10.1016\/j.neurol.2025.07.016_bib0695","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2025.07.016_bib0700","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2025.07.016_bib0705","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.3233\/JAD-231258","article-title":"BACE inhibitor clinical trials for Alzheimer's disease","volume":"101","author":"Watkins","year":"2024","journal-title":"JAD"},{"key":"10.1016\/j.neurol.2025.07.016_bib0710","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0715","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","article-title":"TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease","volume":"3","author":"Shulman","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.neurol.2025.07.016_bib0720","doi-asserted-by":"crossref","first-page":"e2250921","DOI":"10.1001\/jamanetworkopen.2022.50921","article-title":"Analysis of psychological symptoms following disclosure of amyloid\u2013positron emission tomography imaging results to adults with subjective cognitive decline","volume":"6","author":"Caprioglio","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.neurol.2025.07.016_bib0725","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13195-016-0212-z","article-title":"Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review","volume":"8","author":"Bemelmans","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2025.07.016_bib0730","doi-asserted-by":"crossref","first-page":"e0229137","DOI":"10.1371\/journal.pone.0229137","article-title":"Cognitively unimpaired adults\u2019 reactions to disclosure of amyloid PET scan results","volume":"15","author":"Largent","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2025.07.016_bib0735","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13195-021-00840-5","article-title":"Dementia risk communication. A user manual for Brain Health Services\u2014part 3 of 6","volume":"13","author":"Visser","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2025.07.016_bib0740","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jmp\/jhad009","article-title":"Preclinical disease or risk factor? Alzheimer's disease as a case study of changing conceptualizations of disease","volume":"48","author":"Schermer","year":"2023","journal-title":"J Med Philos."},{"key":"10.1016\/j.neurol.2025.07.016_bib0745","doi-asserted-by":"crossref","first-page":"e16302","DOI":"10.1111\/ene.16302","article-title":"What is Alzheimer's disease? An analysis of nosological perspectives from the 20th and 21st centuries","volume":"31","author":"Villain","year":"2024","journal-title":"Euro J Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0750","doi-asserted-by":"crossref","first-page":"e70068","DOI":"10.1002\/alz.70068","article-title":"The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence","volume":"21","author":"Planche","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2025.07.016_bib0755","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1001\/jamaneurol.2025.0142","article-title":"Cognitive phenotyping and interpretation of Alzheimer blood biomarkers","volume":"82","author":"Bouteloup","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2025.07.016_bib0760","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13073-022-01070-6","article-title":"Penetrance estimation of Alzheimer disease in SORL1 loss-of-function variant carriers using a family-based strategy and stratification by APOE genotypes","volume":"14","author":"Schramm","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.neurol.2025.07.016_bib0765","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/brain\/awy327","article-title":"Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration","volume":"142","author":"Tan","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2025.07.016_bib0770","doi-asserted-by":"crossref","first-page":"100576","DOI":"10.1016\/j.lanepe.2022.100576","article-title":"Dementia prevention in memory clinics: recommendations from the European task force for brain health services","volume":"26","author":"Frisoni","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.neurol.2025.07.016_bib0775","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/WAD.0b013e31815a9dcc","article-title":"Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study","volume":"22","author":"Chao","year":"2008","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.neurol.2025.07.016_bib0780","doi-asserted-by":"crossref","first-page":"102538","DOI":"10.1016\/j.eclinm.2024.102538","article-title":"Population-level interventions for the primary prevention of dementia: a complex evidence review","volume":"70","author":"Walsh","year":"2024","journal-title":"eClinicalMedicine"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725005910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725005910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:38:03Z","timestamp":1763177883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378725005910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0035378725005910"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2025.07.016","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The challenging concept of preclinical Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2025.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}